In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, […]
– Menarini Group anuncia nuevos datos sobre ELZONRIS® (tagraxofusp-erzs) que se presentarán en la 67ª Reunión y Exposición Anual de la Sociedad Americana de Hematología Los datos abarcan cinco resúmenes, incluidas dos presentaciones orales con […]
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression. The study was presented by the Menarini […]
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression. The study was presented by the Menarini […]
Die Wirksamkeit von ORSERDU bei der Behandlung von Patientinnen und Patienten mit ER+/HER2-ESR1-Mut Brustkrebs im fortgeschrittenen Stadium oder metastasiertem Brustkrebs (mBC) ist in der Praxis gut belegt. Aktualisierte Ergebnisse von Elacestrant in Kombination mit Abemaciclib […]
